Scientific updates on Triumvira.

January 31, 2025

A Phase 1/2 Study Evaluating the Safety and Efficacy of Autologous TAC-T Cells in Subjects with Claudin 18.2+ Advanced Solid Tumors

Read More

November 9, 2024

A Phase 1/2 Study Evaluating the Safety and Efficacy of Autologous TAC-T Cells in Subjects with Claudin 18.2+ Advanced Solid Tumors

Read More

November 4, 2023

Preclinical Characterization and Modeling of Allogeneic Vγ9Vδ2 TAC T Cells for the Treatment of Solid Tumors

Read More

TAC-T Cells Persist and Remain Functional During and After Repeated Tumor Exposure In Vitor and In Vivo

Read More

A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects with Unresectable, Locally Advanced or Metastatic CLDN18.2+ Solid Tumors

Read More

A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC01-HER2 in Relapsed or Refractory Solid Tumors (TACTIC-2)

Read More